Form 4: PURE Bioscience Director Darin Zehr Acquires Stock Options

Director Darin Zehr acquired stock options in PURE Bioscience, Inc. on August 20, 2024.

Summary

• On August 20, 2024, Darin Zehr, a director of PURE Bioscience, Inc., acquired stock options to purchase 125,000 shares of common stock.
• The exercise price of these options is $0.07 per share.
• The options vest in two tranches: 50% on the earlier of January 15, 2025, or the date of the 2025 annual meeting, and the remaining 50% on the earlier of January 15, 2026, or the date of the 2026 annual meeting.
• The options expire on August 20, 2034.

Sentiment

Score: 6

Explanation: The document itself is neutral, simply reporting a transaction. The grant of options could be viewed as mildly positive, reflecting confidence in the company's future.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

Stock option grants are a common form of executive compensation in publicly traded companies, aligning management's interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in many industries, particularly for smaller companies seeking to attract and retain talent.
• The vesting schedule of 50% in one year and 50% in two years is a fairly typical vesting schedule.
• The exercise price of $0.07 is likely close to the current market price of the stock at the time of the grant.

Stakeholder Impact

• The stock option grant could potentially incentivize the director to work towards increasing shareholder value.

Key Dates

Keywords

stock options, director, PURE Bioscience, Darin Zehr, beneficial ownership, Form 4